Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: L10V 99% (non=21,671) • T12S 99% (non=22,004) • I13V 100% (non=22,009) • G16E 99% (non=21,185) • E35D 99% (non=21,526) • M36I 100% (non=21,534) • R41K 99% (non=22,017) • R57K 99% (non=22,013) • L63T 100% (non=22,017) • H69K 99% (non=21,220) • L89M 99% (non=24,305)

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

PR comments

Other

- **L10I/V** are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: None
RT Other Mutations: K11T 99% (non=22,012) • V21I 97% (non=21,961) • V35T 100% (non=5,385) • T39R 100% (non=220) • V60I 100% (non=222) • L120LS 0.65%, S 99% (non=224) • K122E 100% (non=222) • D123N 100% (non=222) • I135T 92% (non=216) • K173A 100% (non=217) • D177DEG E 69%, D 30%, G 14% • V179VI V 80%, I 17% • T200TA T 75%, A 24% • I202V 100% (non=42) • Q207A 100% (non=79) • R211K 99% (non=75) • V245Q 99% (non=99) • E248D 99% (non=100) • K281R 98% (non=75) • T286A 97% (non=67) • E291D 100% (non=63) • V292VI V 92%, I 10% (non=62) • I293V 94% (non=67) • P294T 100% (non=67) • K512KR K 51%, R 49% (non=1,214) • S519N 100% (non=1,215) • Q524K 99% (non=1,688) • K527G 100% (non=1,807) • E529D 99% (non=1,721) • A554N 99% (non=2,079)

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

RT comments

Other

- **V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: None
IN Other Mutations: V31I 99% (non=1,969) • I60M 97% (non=1,122) • I72V 100% (non=700) • T112IV I 19%, V 14% (non=820) • T124A 100% (non=670) • T125A 100% (non=835) • K136Q 99% (non=802) • E138ED D 94%, E 25% (non=1,013) • D167E 96% (non=2,028) • G193R 100% (non=2,027) • V201I 99% (non=1,811) • Q216N 99% (non=1,846) • L234I 99% (non=2,206) • D256E 99% (non=2,012) • A265ATV A 65%, T 28%, V 13% (non=2,152) • I268IL I 56%, L 43% (non=2,218) • V281M 100% (non=2,195) • S283G 100% (non=2,139)

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN comments

Other

- **E138D** is a polymorphism that occurs in 1% to 2% of viruses from INSTI-naive patients. It does not appear to be selected by INSTIs or to reduce INSTI susceptibility.

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.